EUVIMEDEUVIMED entdecken
Open Access

Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas

Thomas M Cardillo, Maria B Zalath, Roberto Arrojo, Robert M Sharkey, Serengulam V Govindan, Chien-Hsing Chang, David M Goldenberg

Oncotarget · 2024

DOI: 10.18632/oncotarget.28559 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncotarget, 2024. Verfasst von Thomas M Cardillo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Immunomedics, Inc., Morris Plains, NJ 07950 now acquired by Gilead Sciences, Inc., Foster City, CA 94404, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Immunoconjugates, Small Cell Lung Carcinoma, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsImmunoconjugatesSmall Cell Lung CarcinomaUrinary Bladder NeoplasmsLung NeoplasmsCarcinomaAntibodies, Monoclonal, HumanizedHumansUnited StatesAnimalsMiceUrinary BladderPlatinumCisplatinCarboplatinLungCamptothecin

Stichwörter der Autor:innen

SN-38Trop-2carboplatincisplatinsacituzumab govitecan

Substanzen

sacituzumab govitecanPlatinumCisplatinCarboplatinImmunoconjugatesCamptothecinAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Immunomedics, Inc., Morris Plains, NJ 07950 now acquired by Gilead Sciences, Inc., Foster City, CA 94404, USA.
  • Gilead Sciences, Inc., Foster City, CA 94404, USA.
  • At the time the work was conducted, all the authors were employees of Immunomedics, Inc.
  • Current address: Center for Molecular Medicine and Immunology, Mendham, NJ 07945, USA; E-mail, dmg.gscancer@att.net.
  • At the time the work was conducted, this author was Chairman and Chief Scientific Officer of Immunomedics, Inc., which he founded in 1982.

Zitieren

APA

Cardillo, T. M., Zalath, M. B., Arrojo, R., Sharkey, R. M., Govindan, S. V., Chang, C. H., & Goldenberg, D. M. (2024). Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas. Oncotarget. https://doi.org/10.18632/oncotarget.28559

Vancouver

Cardillo TM, Zalath MB, Arrojo R, Sharkey RM, Govindan SV, Chang CH, et al. Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas. Oncotarget. 2024. doi:10.18632/oncotarget.28559

BibTeX
@article{Cardillo2024,
  author = {Cardillo, Thomas M and Zalath, Maria B and Arrojo, Roberto and Sharkey, Robert M and Govindan, Serengulam V and Chang, Chien-Hsing and Goldenberg, David M},
  title = {Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas},
  journal = {Oncotarget},
  year = {2024},
  doi = {10.18632/oncotarget.28559}
}
Kostenlos starten →